2,8-dimethylquinazolin-4(3H)-one | 172462-90-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2,8-dimethylquinazolin-4(3H)-one
• 英文别名: NU 1069；2,8-dimethyl-3H-quinazolin-4-one；2,8-Dimethyl-3H-chinazolin-4-on；2,8-Dimethylquinazolin-4-OL；2,8-dimethyl-3H-quinazolin-4-one
• CAS: 172462-90-7
• 化学式: C₁₀H₁₀N₂O
• 分子量: 174.202
• InChiKey: CJXMJXBJIWEHRP-UHFFFAOYSA-N

物化性质

• 熔点：
  240 °C
• 沸点：
  310.7±35.0 °C(Predicted)
• 密度：
  1.23±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  2,8-dimethylquinazolin-4(3H)-one 、 4-氯苯甲醛 在 溶剂黄146 作用下， 反应 12.0h， 以90.5%的产率得到2-[(E)-2-(4-chlorophenyl)ethenyl]-8-methylquinazolin-4(3H)-one
  参考文献：
  名称：

  Discovery and structure–activity relationships of 4-aminoquinazoline derivatives, a novel class of opioid receptor like-1 (ORL1) antagonists

  摘要：

  Synthesis and structure-activity relationship studies of a series of 4-aminoquinazoline derivatives led to the identification of (1R, 2S)-17, N-[(1R, 2S)-2-({2-[(4-chlorophenyl) carbonyl] amino-6-methylquinazolin-4-yl} amino) cyclohexyl] guanidine dihydrochloride, as a highly potent ORL1 antagonist with up to 3000-fold selectivity over the mu, delta, and kappa opioid receptors. Molecular modeling clarified the structural factors contributing to the high affinity and selectivity of (1R, 2S)-17. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.11.012
• 作为产物：
  描述：

  2-氨基-3-甲基苯甲酰胺 在 吡啶 、 sodium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 2,8-dimethylquinazolin-4(3H)-one
  参考文献：
  名称：

  Griffin; Srinivasan; White, Pharmaceutical Sciences, 1996, vol. 2, # 1, p. 43 - 47

  摘要：

  DOI：

文献信息

• [EN] QUINAZOLINE DERIVATIVES AS PDE10A ENZYME INHIBITORS<br/>[FR] DÉRIVÉS DE QUINAZOLINE EN TANT QU'INHIBITEURS DE L'ENZYME PDE10A
  申请人：LUNDBECK & CO AS H

  公开号：WO2013050527A1

  公开（公告）日：2013-04-11

  This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I.

  这项发明涉及一类PDE10A酶抑制剂化合物。该发明提供了一种包含该发明化合物的治疗有效量和药用可接受载体的药物组合物。本发明还提供了制备式I化合物的方法。本发明还提供了一种治疗患有神经退行性疾病的受试者的方法，包括向受试者施用式I化合物的治疗有效量。本发明还提供了一种治疗患有药物成瘾的受试者的方法，包括向受试者施用式I化合物的治疗有效量。本发明还提供了一种治疗患有精神障碍的受试者的方法，包括向受试者施用式I化合物的治疗有效量。
• Design, Synthesis, and Structure–Activity Relationship of Quinazolinone Derivatives as Potential Fungicides
  作者：Jing-Wen Peng、Xiao-Dan Yin、Hu Li、Kun-Yuan Ma、Zhi-Jun Zhang、Rui Zhou、Yu-Ling Wang、Guan-Fang Hu、Ying-Qian Liu

  DOI：10.1021/acs.jafc.0c05475

  日期：2021.4.28

  Plant diseases caused by phytopathogenic fungi reduce the yield and quality of crops. To develop novel antifungal agents, we designed and synthesized eight series of quinazolinone derivatives and evaluated their anti-phytopathogenic fungal activity. The bioassay results revealed that compounds KZL-15, KZL-22, 5b, 6b, 6c, 8e, and 8f exhibited remarkable antifungal activity in vitro. Especially, compound

  由植物致病真菌引起的植物病害降低了作物的产量和质量。为了开发新型的抗真菌剂，我们设计并合成了8个系列的喹唑啉酮衍生物，并评估了它们的抗植物病原性真菌活性。生物测定结果表明，化合物KZL-15，KZL-22，图5b，图6b，图6c，图8E和图8F显示出显着的抗真菌活性在体外。尤其是，化合物6c对巩膜核盘菌，Satellakis sasakii，镰刀镰刀菌（Fusarium graminearum）和尖孢镰刀菌（Fusarium oxysporum）的IC 50值（抑制浓度50％）分别为2.46、2.94、6.03和11.9μg/ mL。进一步的机制询问显示，用化合物6c处理的菌核菌中菌丝异常，细胞器受损和细胞膜通透性改变。另外，体内生物测定法表明，化合物6c在100μg/ mL浓度下对核盘菌的治疗和保护作用（分别为87.3和90.7％）可与阳性对照嘧菌酯（分别为89.5和91.2％）相媲美。这项工作验证了化合物6c的潜力
• Fe₃O₄nanoparticle-supported copper(I): magnetically recoverable and reusable catalyst for the synthesis of quinazolinones and bicyclic pyrimidinones
  作者：Lin Yu、Min Wang、Pinhua Li、Lei Wang

  DOI：10.1002/aoc.2902

  日期：2012.11

  A highly efficient, easily recoverable and reusable Fe3O4 magnetic nanoparticle‐supported Cu(I) catalyst has been developed for the synthesis of quinazolinones and bicyclic pyrimidinones. In the presence of supported Cu(I) catalyst (10 mol%), amidines reacted with substituted 2‐halobenzoic acids and 2‐bromocycloalk‐1‐enecarboxylic acids to generate the corresponding N‐heterocycle products in good to

  已经开发出了一种高效，易于回收和可重复使用的Fe 3 O 4磁性纳米粒子负载的Cu（I）催化剂，用于合成喹唑啉酮和双环嘧啶酮。在负载型Cu（I）催化剂（10 mol％）的存在下，am与取代的2-卤代苯甲酸和2-溴代环烷基-1-烯羧酸反应生成相应的N杂环产物，在室温下室温下具有良好或优异的收率。 DMF。另外，负载的Cu（I）催化剂可被回收至少10次而不会显着损失其催化活性。版权所有©2012 John Wiley＆Sons，Ltd.
• Copper(I) Iodide Catalyzed Domino Process to Quinazolin-4(3<i>H</i>)-ones
  作者：Ke Ding、Jing Zhou、Liangbing Fu、Man Lv、Jinsong Liu、Duanqing Pei

  DOI：10.1055/s-0028-1083245

  日期：2008.12

  An efficient synthesis of substituted quinazolin-4(3H)-ones by a one-pot ligand-free CuI-catalyzed coupling/condensative cyclization under mild conditions is described. Our study provides an alternative strategy for the preparation of biologically active quinazolin-4(3H)-ones.

  本文描述了一种在温和条件下，通过一步法无配体CuI催化的耦合/冷凝环化反应高效合成替代取代的喹嗪啉-4(3H)-酮的方法。我们的研究提供了一种制备生物活性喹嗪啉-4(3H)-酮的替代策略。
• Benzamide analogs useful as PARP (ADP-ribosyltransferase, ADPRT) DNA
  申请人：Newcastle University Ventures Limited

  公开号：US05756510A1

  公开（公告）日：1998-05-26

  A range of 3-oxybenzamide compounds and related quinazolinone compounds are disclosed which can act as potent inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase or PARP enzyme (EC 2.4.2.30), and which thereby can provide useful therapeutic compounds for use in conjunction with DNA-damaging cytotoxic drugs or radiotherapy to potentiate the effects of the latter. The compounds disclosed include 3-benzyloxybenzamides, 3-oxybenzamides in which a chain of 5 or more methylene groups terminate in a halogen atom or in a purin-9-yl moiety, certain benzoxazole-4-carboxamide compounds and certain quinazolinone compounds. In formula X and Y together may form a bride --X--Y-- that represents the grouping (a), (b) or (c )wherein R.sup.5 is H, alkyl, aryl or aralkyl.

  揭示了一系列3-氧苯甲酰胺化合物和相关的喹唑啉酮化合物，它们可以作为DNA修复酶聚(ADP-核糖)聚合酶或PARP酶（EC 2.4.2.30）的有效抑制剂，并且因此可以提供用于与损伤DNA的细胞毒性药物或放疗结合使用以增强后者效果的有用治疗化合物。所披露的化合物包括3-苄氧基苯甲酰胺、3-氧基苯甲酰胺，其中5个或更多亚甲基基团的链以卤原子或吡嗪-9-基团结尾，某些苯并噁唑-4-甲酰胺化合物和某些喹唑啉酮化合物。在公式X和Y中，X和Y一起可以形成代表基团(a)、(b)或(c)的桥--X--Y--，其中R.sup.5为H、烷基、芳基或芳基烷基。